Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980833 | 0.92 | CCNT1 (0.39) | CCNT1CDK9CYP4F2CYP4A11GPR119 | |
| SCHEMBL979908 | 0.92 | CCNT1 (0.39) | CCNT1CDK9CYP4F2CYP4A11GPR119 | |
| SCHEMBL1048473 | 0.89 | CCNT1 (0.37) | CCNT1CDK9CYP4F2CYP4A11GPR119 | |
| SCHEMBL10040266 | 0.89 | CCNT1 (0.41) | CCNT1CDK9CYP4F2CYP4A11 | |
| SCHEMBL980281 | 0.83 | TDP1 (0.48) | CCNT1CDK9CYP4F2CYP4A11SYK | |
| SCHEMBL10040265 | 0.83 | PTGDR (0.40) | CCNT1CDK9GPR119MMP13SYK | |
| SCHEMBL982440 | 0.83 | GPR119 (0.54) | CCNT1CDK9CYP4F2CYP4A11GPR119 | |
| SCHEMBL977871 | 0.82 | GPR119 (0.53) | GPR119MMP13 | |
| SCHEMBL979246 | 0.82 | GPR119 (0.40) | CCNT1CDK9GPR119SYK | |
| SCHEMBL979614 | 0.82 | GPR119 (0.40) | CCNT1CDK9CYP4F2CYP4A11GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207344-B2 | GPR119 agonists | ELI LILLY AND COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110015199-A1 | GPR119 Agonists | ELI LILLY AND COMPANY (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015199-A1 | GPR119 Agonists | GPR119, GLP1R, GCGR | CCNT1 4475/4885CDK9 2128/4885CYP4F2 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.